Viewing Study NCT03360006

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-26 @ 1:19 PM
Ignite Modification Date: 2026-02-04 @ 11:39 AM
Study NCT ID: NCT03360006
Status: TERMINATED
Last Update Posted: 2021-03-24
First Post: 2017-11-28
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer
Sponsor: AbbVie
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Acute Myeloid Leukemia (AML) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Acute Myeloid Leukemia (AML) View
None Relapsed/refractory acute myeloid leukemia View
None Dose-limiting toxicity View
None Recommended phase two dose View
None Pharmacokinetics View